A cell-based test system for the assessment of pharmacokinetics of NOD1 and NOD2 receptor agonists.
Int Immunopharmacol
; 63: 94-100, 2018 Oct.
Article
em En
| MEDLINE
| ID: mdl-30077058
ABSTRACT
Agonists of nucleotide oligomerization domain (NOD) 1 and NOD2 receptors represent a promising class of immunostimulants and immunological adjuvants. Here, we describe a cell-based test system to assess their pharmacokinetics. In this system, NOD1 and NOD2 agonist concentrations in sera are determined using a reporter cell line, 293Luc, which contains an NF-κB-inducible luciferase reporter construct and naturally expresses NOD1 and NOD2. The 293Luc cells dose-dependently respond to different NOD1 and NOD2 agonists in the nanomolar to low-micromolar concentration range. To verify that the NF-κB-inducing activity of serum samples is due to the administered agonist and not to secondarily induced endogenous molecules, a 293Luc-derived NOD1/NOD2 double-knockout clone is used. Within-run and between-run precisions of the system are <15% and <20%, respectively. Applicability of the novel assay is illustrated by studying pharmacokinetics of two specific NOD2 agonists (NacetyldglucosaminylNacetyldmuramyllalanyldisoglutamine and Nglycolyldmuramyllalanyldisoglutamine) and a specific NOD1 agonist (NacetyldglucosaminylNacetyldsorbitolaminedlactoyllalanyldisoglutamylmesodiaminopimelic acid). In summary, the test system described here can potentially be used to assess pharmacokinetics of NOD1 and NOD2 agonists in different animal species.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Bioensaio
/
Proteína Adaptadora de Sinalização NOD1
/
Proteína Adaptadora de Sinalização NOD2
/
Glutamina
Limite:
Animals
/
Humans
/
Male
Idioma:
En
Revista:
Int Immunopharmacol
Ano de publicação:
2018
Tipo de documento:
Article